Biontech Se Stock Performance
| BNTX Stock | USD 117.39 3.17 2.78% |
BioNTech has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.46, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioNTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioNTech is expected to be smaller as well. BioNTech SE right now shows a risk of 2.64%. Please confirm BioNTech SE information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if BioNTech SE will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, BioNTech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (5.12) | Five Day Return (4.78) | Year To Date Return 1.66 | Ten Year Return 702.11 | All Time Return 702.11 |
Dividend Date 2022-06-17 | Ex Dividend Date 2022-06-02 |
1 | BioNTech Rating Increased to Overweight at Morgan Stanley | 09/26/2024 |
2 | Up Over 600 percent in 2024, Can Summit Therapeutics Stock Keep Rising | 10/24/2024 |
3 | Stocks making the biggest moves premarket Pinterest, Monster Beverage, Bath Body Works, Trump Media more | 11/08/2024 |
4 | BioNTechs Options A Look at What the Big Money is Thinking | 11/15/2024 |
5 | Four trades working this morning amid rising geopolitical tensions | 11/19/2024 |
6 | The market is having knee-jerk reactions to Trumps picks. That could spell buying opportunities | 11/21/2024 |
7 | Why Is BioNTech SE Among the Best High Growth Healthcare Stocks to Invest In Now | 12/02/2024 |
8 | Redmile Group LLC Invests 18.35 Million in BioNTech SE | 12/05/2024 |
9 | Heres Why Summit Therapeutics Stock Price Rose 6 percent on Friday | 12/09/2024 |
10 | 2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid | 12/11/2024 |
| Begin Period Cash Flow | 13.9 B |
BioNTech |
BioNTech Relative Risk vs. Return Landscape
If you would invest 11,562 in BioNTech SE on September 18, 2024 and sell it today you would earn a total of 178.00 from holding BioNTech SE or generate 1.54% return on investment over 90 days. BioNTech SE is currently generating 0.0582% in daily expected returns and assumes 2.6445% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than BioNTech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioNTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioNTech SE, and traders can use it to determine the average amount a BioNTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.022
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | BNTX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.64 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average BioNTech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNTech by adding it to a well-diversified portfolio.
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | -0.024 | ||||
| Return On Asset | -0.0124 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 10.08 B | ||||
| Shares Outstanding | 239.74 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 9.01 X | ||||
| Revenue | 3.82 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | 1.09 B | ||||
| Net Income | 1.19 B | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 219.1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 79.73 X | ||||
| Cash Flow From Operations | 5.37 B | ||||
| Earnings Per Share | (1.93) X | ||||
| Market Capitalization | 27.38 B | ||||
| Total Asset | 23.01 B | ||||
| Retained Earnings | 19.76 B | ||||
| Working Capital | 17.46 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
About BioNTech Performance
Evaluating BioNTech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioNTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 217.67 | 228.56 | |
| Return On Tangible Assets | 0.04 | 0.06 | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | 0.04 | 0.07 | |
| Return On Equity | 0.05 | 0.04 |
Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNTech SE has a very strong financial position based on the latest SEC filings | |
| About 62.0% of the company shares are held by company insiders | |
| Latest headline from fool.com: 2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.